Log in

NASDAQ:RARXRa Pharmaceuticals Stock Price, Forecast & News

$47.99
0.00 (0.00 %)
(As of 04/2/2020)
Add
Compare
Today's Range
$47.99
Now: $47.99
$47.99
50-Day Range
$47.99
MA: $47.99
$48.00
52-Week Range
$19.64
Now: $47.99
$48.02
Volume30,200 shs
Average Volume1.16 million shs
Market Capitalization$2.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Ra Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$5.56 per share

Profitability

Net Income$-102,690,000.00

Miscellaneous

Employees72
Market Cap$2.27 billion
Next Earnings DateN/A
OptionableOptionable

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

How has Ra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ra Pharmaceuticals' stock was trading at $45.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RARX shares have increased by 4.4% and is now trading at $47.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ra Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ra Pharmaceuticals.

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.16. View Ra Pharmaceuticals' earnings history.

What price target have analysts set for RARX?

10 brokerages have issued 12 month price objectives for Ra Pharmaceuticals' shares. Their forecasts range from $48.00 to $48.00. On average, they anticipate Ra Pharmaceuticals' stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Media stories about RARX stock have trended extremely negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutRa Pharmaceuticals.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the following people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read, Chief Scientific Officer (Age 48)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.39%), Alpine Associates Management Inc. (4.24%), Magnetar Financial LLC (3.55%), JPMorgan Chase & Co. (3.51%), State Street Corp (3.48%) and CNH Partners LLC (2.52%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View institutional ownership trends for Ra Pharmaceuticals.

Which major investors are selling Ra Pharmaceuticals stock?

RARX stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., CNH Partners LLC, Alliancebernstein L.P., Magnetar Financial LLC, Alpine Associates Management Inc., Wellington Management Group LLP, BlackRock Inc., and Rafferty Asset Management LLC. Company insiders that have sold Ra Pharmaceuticals company stock in the last year include Alonso Ricardo, Ramin Farzaneh-Far, and Simon Read. View insider buying and selling activity for Ra Pharmaceuticals.

Which major investors are buying Ra Pharmaceuticals stock?

RARX stock was bought by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, JPMorgan Chase & Co., Alyeska Investment Group L.P., Gabelli Funds LLC, Omni Partners LLP, Athanor Capital LP, Healthcare of Ontario Pension Plan Trust Fund, and Balyasny Asset Management LLC. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, and Rajeev M Shah. View insider buying and selling activity for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $47.99.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $2.27 billion and generates $3 million in revenue each year. The company earns $-102,690,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is www.rapharma.com.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.